PL424453A1 - Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) - Google Patents

Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Info

Publication number
PL424453A1
PL424453A1 PL424453A PL42445318A PL424453A1 PL 424453 A1 PL424453 A1 PL 424453A1 PL 424453 A PL424453 A PL 424453A PL 42445318 A PL42445318 A PL 42445318A PL 424453 A1 PL424453 A1 PL 424453A1
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
perenchymatous
inhibitors
Prior art date
Application number
PL424453A
Other languages
English (en)
Inventor
Christopher Turski
Original Assignee
Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością filed Critical Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL424453A priority Critical patent/PL424453A1/pl
Priority to MX2020007990A priority patent/MX2020007990A/es
Priority to RU2020125051A priority patent/RU2782919C2/ru
Priority to KR1020207025024A priority patent/KR20200116144A/ko
Priority to EP19747045.3A priority patent/EP3746107A4/en
Priority to CA3088969A priority patent/CA3088969A1/en
Priority to CN201980011178.7A priority patent/CN111989112A/zh
Priority to US16/964,984 priority patent/US20210047352A1/en
Priority to PCT/PL2019/000013 priority patent/WO2019151883A1/en
Publication of PL424453A1 publication Critical patent/PL424453A1/pl
Priority to ZA2019/05958A priority patent/ZA201905958B/en
Priority to IL275994A priority patent/IL275994A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Zgłoszenie dotyczy nowego zastosowania pochodnych benzazepiny, benzoksazepiny, kwasu benzotiazepino-N-octowego oraz fosfono-podstawionego benzazepinonu o aktywności hamującej obojętną endopeptydazę (NEP) i/lub ludzką rozpuszczalną endopeptydazę (hSEP). Związki te są stosowane do wytwarzania kompozycji farmaceutycznych zmniejszających szkodliwy wpływ bezobjawowo postępującego rozsianego niedoboru perfuzji narządów miąższowych, lub ich części, mogącego sugerować rozwój chorób układowych.
PL424453A 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) PL424453A1 (pl)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
CA3088969A CA3088969A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
RU2020125051A RU2782919C2 (ru) 2018-01-31 2019-01-31 ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (НЭП) И РАСТВОРИМОЙ ЭНДОПЕПТИДАЗЫ ЧЕЛОВЕКА (РЭПч) ДЛЯ УМЕНЬШЕНИЯ ВРЕДНЫХ ВОЗДЕЙСТВИЙ ПЕРФУЗИОННОГО ДЕФИЦИТА ОРГАНОВ
KR1020207025024A KR20200116144A (ko) 2018-01-31 2019-01-31 기관의 관류 결핍의 해로운 효과를 감소시키기 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제
EP19747045.3A EP3746107A4 (en) 2018-01-31 2019-01-31 NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (HSEP) INHIBITORS TO REDUCE THE HARMFUL EFFECTS OF ORGAN PERFUSION DEFICIENCY
MX2020007990A MX2020007990A (es) 2018-01-31 2019-01-31 Inhibidores de endopeptidasa neutra (nep) y endopeptidasa soluble humana (hsep) para reducir efectos perjudiciales de la deficiencia de perfusion de organos.
CN201980011178.7A CN111989112A (zh) 2018-01-31 2019-01-31 用于减少器官灌流不足的有害效应的中性内肽酶(nep)及人类可溶性内肽酶(hsep)抑制剂
US16/964,984 US20210047352A1 (en) 2018-01-31 2019-01-31 NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS TO REDUCE DETRIMENTAL EFFECTS OF PERFUSION DEFICIENCY OF PARENCHYMAL ORGANS
PCT/PL2019/000013 WO2019151883A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
ZA2019/05958A ZA201905958B (en) 2018-01-31 2019-09-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
IL275994A IL275994A (en) 2018-01-31 2020-07-12 Human neutral endopeptidase and soluble endopeptidase inhibitors to reduce harmful effects of organ hypoperfusion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Publications (1)

Publication Number Publication Date
PL424453A1 true PL424453A1 (pl) 2019-08-12

Family

ID=67478773

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Country Status (10)

Country Link
US (1) US20210047352A1 (pl)
EP (1) EP3746107A4 (pl)
KR (1) KR20200116144A (pl)
CN (1) CN111989112A (pl)
CA (1) CA3088969A1 (pl)
IL (1) IL275994A (pl)
MX (1) MX2020007990A (pl)
PL (1) PL424453A1 (pl)
WO (1) WO2019151883A1 (pl)
ZA (1) ZA201905958B (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL184336B1 (pl) * 1995-03-23 2002-10-31 Solvay Pharm Gmbh Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AR046454A1 (es) * 2003-11-18 2005-12-07 Solvay Pharm Gmbh Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
WO2005112940A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and pde v inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL184336B1 (pl) * 1995-03-23 2002-10-31 Solvay Pharm Gmbh Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOGNA BROCKHUIS, ZABURZENIA PERFUZJI MÓZGOWEJ OCENIONE METODĄ TOMOGRAFII EMISYJNEJ POJEDYNCZEGO FOTONU (SPECT) U PACJENTÓW Z OTĘPIENIEM Z CIAŁAMI LEWY'EGO, CHOROBĄ PARKINSONA ORAZ CHOROBĄ ALZHEIMERA, 2009 *

Also Published As

Publication number Publication date
US20210047352A1 (en) 2021-02-18
CN111989112A (zh) 2020-11-24
IL275994A (en) 2020-08-31
ZA201905958B (en) 2021-07-28
RU2020125051A (ru) 2022-02-28
EP3746107A4 (en) 2022-01-12
WO2019151883A1 (en) 2019-08-08
RU2020125051A3 (pl) 2022-02-28
KR20200116144A (ko) 2020-10-08
CA3088969A1 (en) 2019-08-08
EP3746107A1 (en) 2020-12-09
MX2020007990A (es) 2020-09-09

Similar Documents

Publication Publication Date Title
CO2022003782A2 (es) Inhibidores de kras g12d
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
PH12016500024A1 (en) Bromodomain inhibitor
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
EA201591499A1 (ru) Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
EA201690888A1 (ru) Новые гетероциклические соединения
EA201992679A1 (ru) N-замещенные индольные производные
ECSP066931A (es) Nuevos imidazoles
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
AR063027A1 (es) Derivados de sulfonamida
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола